氩氦刀冷冻消融治疗老年早期非小细胞肺癌的临床疗效观察

目的:观察氩氦刀冷冻消融治疗老年早期非小细胞肺癌的疗效及安全性。方法:非小细胞肺癌（NSCLC)患者28 例，经病理或细胞学确诊，不愿接受手术或无手术适应证的早期（I期及部分II期）的70岁以上老年患者，全部行CT引导氩氦刀冷冻消融术，观察局部病灶变化、疗效、并发症及生存情况。结果:术后1个月复查CT，按实体瘤评价标准缓解率（CR+PR)为71.4%（20/28）。术后3个月及6个月评价疗效（CR+PR)分别为67.9%和64.3%。1~2年随访过程中7例（25.0%）出现转移，其中5例患者出现纵隔淋巴结转移，2例患者出现远处转移，死亡2例，21例（75.0%）患者未见肿瘤复发或转移征象。所有患者均未出现严重并发症。结论:氩氦刀冷冻消融治疗老年早期非小细胞肺癌疗效较好，安全性高，是老年早期NSCLC治疗的新选择，具有较好的临床应用前景。

Clinical study of cryoablation in the treatment of older patients with early stage(I/II)non-small cell lung cancer

Objective:To observe the clinical efficacy and safety of cryoablation in the treatment of older patients with early stage non -small cell lung cancer (NSCLC).Methods:A total of 28 NSCLC older patients(stage I -II) received cryoablation.All patients were followed -up for 12 ~24 months after operation,using contrast -enhanced CT to evaluate the tumor size and enhancement.Results:After 1 month,according to RECIST criteria,the remission rate (CR +PR)was 71.4%.The remission rate after 3 and 6 months was 67.9% and 64.3% respectively.The existence rate in one year was 96.4%.Conclusion:CT -guided percutanous cryoablation may achieve high response rate.It is a simple,safe and reliable procedure for older patients with NSCLC in early stage.It has excellent prospect for clinical applications.